Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4657-4665

  Singh, Shivani ^a   Kubler, Andre ^a   Singh, Utpal K ^b   Singh, Ajay ^b   Gardiner, Harriet ^a   Prasad, Rajniti ^c   Elkington, Paul T ^a,d   Friedland, Jon S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NALANDA UNIVERSITY   (India)

^c BANARAS HINDU UNIVERSITY   (India)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITUBERCULAR AGENTS; AZITHROMYCIN; FLUOROQUINOLONES; ISOENZYMES; ISONIAZID; MATRIX METALLOPROTEINASES; MOXIFLOXACIN; RIFAMPIN;

BRONCHOALVEOLAR LAVAGE FLUID; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; EPITHELIAL CELLS; FIBROBLASTS; GROWTH AND DEVELOPMENT; HUMANS; LUNG; METABOLISM; MICROBIOLOGY; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; PRIMARY CELL CULTURE; STROMAL CELLS; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; AZITHROMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; EPITHELIAL CELLS; FIBROBLASTS; FLUOROQUINOLONES; HUMANS; ISOENZYMES; ISONIAZID; LUNG; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; PRIMARY CELL CULTURE; RIFAMPIN; STROMAL CELLS; TUBERCULOSIS, PULMONARY;

EID: 84905375090     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02141-13     Document Type: Article

References (66)

1. Elkington PT, Friedland JS. 2006. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 61:259-266. http://dx.doi.org/10.1136/ thx.2005.051979.
2. Russell DG. 2007. Who puts the tubercle in tuberculosis? Nat. Rev. Microbiol. 5:39-47. http://dx.doi.org/10.1038/nrmicro1538.
3. Brinckerhoff CE, Matrisian LM. 2002. Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol. 3:207-214. http://dx.doi.org/10.1038/nrm763.
4. Parks WC, Wilson CL, Lopez-Boado YS. 2004. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4:617-629. http://dx.doi.org/10.1038/nri1418.
5. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. 1997. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 277:2002-2004. http://dx.doi.org/10.1126/science.277.5334.2002.
6. Finlay GA, Russell KJ, McMahon KJ, D'Arcy E, Masterson M J B, Fitz Gerald MX, O'Connor CM. 1997. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 52:502-506. http://dx.doi.org/10.1136/thx.52.6.502.
7. Manoury B, Nenan S, Guenon I, Lagente V, Boichot E. 2007. Influence of early neutrophil depletion on MMPs/TIMP-1 balance in bleomycininduced lung fibrosis. Int. Immunopharmacol. 7:900-911. http://dx.doi.org/10.1016/j.intimp. 2007.02.009.
8. Jumper C, Cobos E, Lox C. 2004. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) inpatients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir. Med. 98:173-177. http://dx.doi.org/10.1016/j.rmed.2003.08.014.
9. Imai K, Dalal SS, Chen ES, Downey R, Schulman LL, Ginsburg M, D'Armiento J. 2001. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am. J. Respir. Crit. Care Med. 163:786-791. http://dx.doi.org/10.1164/ajrccm.163.3.2001073.
10. Kodate M, Kasai T, Hashimoto H, Yasumoto K, Iwata Y, Manabe H. 1997. Expressionof matrix metalloproteinase (gelatinase) inT1 adenocarcinoma of the lung. Pathol. Int. 47:461-469. http://dx.doi.org/10.1111/j.1440-1827.1997. tb04525.x.
11. Price NM, Farrar J, Tran TT, Nguyen TH, Tran TH, Friedland JS. 2001. Identification of a matrix-degrading phenotype in human tuberculosis in vitro and in vivo. J. Immunol. 166:4223-4230. http://dx.doi.org/10.4049/jimmunol.166. 6.4223.
12. Elkington PT, D'Armiento JM, Friedland JS. 2011. Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. Sci. Transl. Med. 3:71ps6. http://dx.doi.org/10.1126/scitranslmed.3001847.
13. Salgame P. 2011. MMPs in tuberculosis: granuloma creators and tissue destroyers. J. Clin. Invest. 121:1686-1688. http://dx.doi.org/10.1172/JCI57423.
14. Elkington P, Shiomi T, Breen R, Nuttall RK, Ugarte-Gil CA, Walker NF, Saraiva L, Pedersen B, Mauri F, Lipman M, Edwards DR, Robertson BD, D'Armiento J, Friedland JS. 2011. MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J. Clin. Invest. 121:1827-1833. http://dx.doi.org/10.1172/ JCI45666.
15. Walker NF, Clark SO, Oni T, Andreu N, Tezera L, Singh S, Saraiva L, Pedersen B, Kelly DL, Tree JA, D'Armiento JM, Meintjes G, Mauri FA, Williams A, Wilkinson RJ, Friedland JS, Elkington PT. 2012. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am. J. Respir. Crit. Care Med. 185:989-997. http://dx.doi.org/10.1164/rccm.201110-1769OC.
16. Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L. 2010. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 327:466-469. http://dx.doi.org/10.1126/science. 1179663.
17. Wickremasinghe MI, Thomas LH, Friedland JS. 1999. Pulmonary epithelial cells are a source of IL-8 in the response to Mycobacterium tuberculosis: essential role of IL-1 from infected monocytes in a NF-kappa B-dependent network. J. Immunol. 163:3936-3947.
18. Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, Luster AD. 1999. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J. Immunol. 162:3549-3558.
19. Elkington PT, Emerson JE, Lopez-Pascua LD, O'Kane CM, Horncastle DE, Boyle JJ, Friedland JS. 2005. Mycobacterium tuberculosis upregulates matrix metalloproteinase-1 secretion from human airway epithelial cells via a p38 MAPK switch. J. Immunol. 175:5333-5340. http://dx.doi.org/10.4049/jimmunol.175.8. 5333.
20. Elkington PT, Green JA, Emerson JE, Lopez-Pascua LD, Boyle JJ, O'Kane CM, Friedland JS. 2007. Synergistic up-regulation of epithelial cell matrix metalloproteinase-9 secretion in tuberculosis. Am. J. Respir. Cell Mol. Biol. 37:431-437. http://dx.doi.org/10.1165/rcmb.2007-0011OC.
21. O'Kane CM, Elkington PT, Friedland JS. 2008. Monocyte-dependent oncostatin M and TNF-alpha synergize to stimulate unopposed matrix metalloproteinase-1/3 secretion from human lung fibroblasts in tuberculosis. Eur. J. Immunol. 38:1321-1330. http://dx.doi.org/10.1002/eji.200737855.
22. Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE. 2009. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373:1183-1189. http://dx.doi.org/10.1016/ S0140-6736 (09) 60333-0.
23. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE. 2009. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 180:273-280. http://dx.doi.org/10.1164/rccm.200901-0078OC.
24. Dalhoff A, Shalit I. 2003. Immunomodulatory effects of quinolones. Lancet Infect. Dis. 3:359-371. http://dx.doi.org/10.1016/S1473-3099 (03) 00658-3.
25. Stephenson AL, Wu W, Cortes D, Rochon PA. 2013. Tendon injury and fluoroquinolone use: a systematic review. Drug Saf. 36:709-721. http://dx.doi.org/10.1007/s40264-013-0089-8.
26. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. 2006. Antiinflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem. Biophys. Res. Commun. 350:977-982. http://dx.doi.org/10.1016/j. bbrc.2006.09.132.
27. Ishizawa K, Suzuki T, Yamaya M, Jia YX, Kobayashi S, Ida S, Kubo H, Sekizawa K, Sasaki H. 2005. Erythromycin increases bactericidal activity of surface liquid in human airway epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 289:L565-L573. http://dx.doi.org/10.1152/ajplung.00316.2004.
28. Yuhas Y, Azoulay-Alfaguter I, Berent E, Ashkenazi S. 2007. Rifampin inhibits prostaglandin E2 production and arachidonic acid release in human alveolar epithelial cells. Antimicrob. Agents Chemother. 51:4225-4230. http://dx.doi.org/10.1128/AAC.00985-07.
29. Rand L, Green JA, Saraiva L, Friedland JS, Elkington PT. 2009. Matrix metalloproteinase-1 is regulated in tuberculosis by a p38 MAPK-dependent, p-aminosalicylic acid-sensitive signaling cascade. J. Immunol. 182:5865-5872. http://dx.doi.org/10.4049/jimmunol.0801935.
30. World Health Organization. 2011. Global tuberculosis control 2011. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/ global-report/2011/en/.
31. Lawson L, Yassin MA, Thacher TD, Olatunji OO, Lawson JO, Akingbogun TI, Bello CS, Cuevas LE, Davies PD. 2008. Clinical presentation of adults with pulmonary tuberculosis with and without HIV infection in Nigeria. Scand. J. Infect. Dis. 40:30-35. http://dx.doi.org/10.1080/00365540701509899.
32. Den Boon S, Bateman ED, Enarson DA, Borgdorff MW, Verver S, Lombard CJ, Irusen E, Beyers N, White NW. 2005. Development and evaluation of a new chest radiograph reading and recording system for epidemiological surveys of tuberculosis and lung disease. Int. J. Tuberc. Lung Dis. 9:1088-1096.
33. Dawson R, Masuka P, Edwards DJ, Bateman ED, Bekker LG, Wood R, Lawn SD. 2010. Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. Int. J. Tuberc. Lung Dis. 14:52-58.
34. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, Van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, De Beule K, Andries K, Mc Neeley DF. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360:2397-2405. http://dx.doi.org/10.1056/NEJMoa0808427.
35. Ralph AP, Ardian M, Wiguna A, Maguire GP, Becker NG, Drogumuller G, Wilks MJ, Waramori G, Tjitra E, Sandjaja Kenagalem E, Pontororing GJ, Anstey NM, Kelly PM. 2010. A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax 65:863-869. http://dx.doi.org/10.1136/thx.2010.136242.
36. Elkington PT, Green JA, Friedland JS. 2006. Filter sterilization of highly infectious samples to prevent false negative analysis of matrix metalloproteinase activity. J. Immunol. Methods 309:115-119. http://dx.doi.org/10.1016/j.jim.2005.11.010.
37. Leber TM, Balkwill FR. 1997. Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal. Biochem. 249:24-28. http://dx.doi.org/10.1006/abio.1997.2170.
38. Nuttall RK, Pennington CJ, Taplin J, Wheal A, Yong VW, Forsyth PA, Edwards DR. 2003. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol. Cancer Res. 1:333-345.
39. Capitano B, Mattoes HM, Shore E, O'Brien A, Braman S, Sutherland C, Nicolau DP. 2004. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 125:965-973. http://dx.doi.org/10.1378/chest.125.3.965.
40. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. 1999. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 44:835-838. http://dx.doi.org/10.1093/jac/44.6.835.
41. Greenlee KJ, Werb Z, Kheradmand F. 2007. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol. Rev. 87:69-98. http://dx.doi.org/10.1152/physrev. 00022.2006.
42. Chadha VK, Sarin R, Narang P, John KR, Chopra KK, Jitendra R, Mendiratta DK, Vohra V, Shashidhara AN, Muniraj G, Gopi PG, Kumar P. 2013. Trends in the annual risk of tuberculous infection in India. Int. J. Tuberc. Lung Dis. 17:312-319. http://dx.doi.org/10.5588/ijtld.12.0330.
43. Akachi Y, Zumla A, Atun R. 2012. Investing in improved performance of national tuberculosis programs reduces the tuberculosis burden: analysis of 22 high-burden countries, 2002-2009. J. Infect. Dis. 205(Suppl 2):S284-S292. http://dx.doi.org/10.1093/infdis/jis189.
44. Sisodia RS, Jain DK, Agarwal SS, Gupta A. 2011. TB control in India-efforts, challenges and priorities. J. Indian Med. Assoc. 109:921-924, 928.
45. Jain RC. 2011. Tuberculosis-challenges and opportunities. Indian J. Tuberc. 58:148-154.
46. Kumar A. 2012. Status report on RNTCP. Indian J. Tuberc. 59:107-111.
47. Oxlade O, Murray M. 2012. Tuberculosis and poverty: why are the poor at greater risk in India? PLoS One 7:e47533. http://dx.doi.org/10.1371/journal. pone.0047533.
48. Behera D. 2012. Totally drug resistant tuberculosis-a fact or myth? Indian J. Tuberc. 59:190-193.
49. Behera D. 2012. New strategies of TB control in India: are we on the right track? Indian J. Tuberc. 59:130-134.
50. Porwal C, Kaushik A, Makkar N, Banavaliker JN, Hanif M, Singla R, Bhatnagar AK, Behera D, Pande JN, Singh UB. 2013. Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region. PLoS One 8:e55299. http://dx.doi.org/10.1371/journal.pone.0055299.
51. Hrabec E, Strek M, Zieba M, Kwiatkowska S, Hrabec Z. 2002. Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. Int. J. Tuberc. Lung Dis. 6:713-719.
52. Sheen P, O'Kane CM, Chaudhary K, Tovar M, Santillan C, Sosa J, Caviedes L, Gilman RH, Stamp G, Friedland JS. 2009. High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation. Eur. Respir. J. 33:134-141. http://dx.doi.org/10.1183/09031936.00127807.
53. Green JA, Elkington PT, Pennington CJ, Roncaroli F, Dholakia S, Moores RC, Bullen A, Porter JC, Agranoff D, Edwards DR, Friedland JS. 2010. Mycobacterium tuberculosis upregulates microglial matrix metalloproteinase-1 and -3 expression and secretion via NF-kappaB- and activator protein-1-dependent monocyte networks. J. Immunol. 184:6492-6503. http://dx.doi.org/10.4049/ jimmunol.0903811.
54. Shalit I, Halperin D, Haite D, Levitov A, Romano J, Osherov N, Fabian I. 2006. Anti-inflammatory effects of moxifloxacin on IL-8, IL-1beta and TNF-alpha secretion and NFkappaB and MAP-kinase activation in human monocytes stimulated with Aspergillus fumigatus. J. Antimicrob. Chemother. 57:230-235. http://dx.doi.org/10.1093/jac/dki441.
55. Blau H, Klein K, Shalit I, Halperin D, Fabian I. 2007. Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line. Am. J. Physiol. Lung Cell. Mol. Physiol. 292:L343-L352. http://dx.doi.org/10.1152/ ajplung.00030.2006.
56. Elkington PT, Nuttall RK, Boyle JJ, O'Kane CM, Horncastle DE, Edwards DR, Friedland JS. 2005. Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1. Am. J. Respir. Crit. Care Med. 172:1596-1604. http://dx.doi.org/10.1164/rccm.200505-753OC.
57. Zhanel GG, Noreddin AM. 2001. Pharmacokinetics and pharmacodynamicsofthe new fluoroquinolones: focus onrespiratory infections. Curr. Opin. Pharmacol. 1:459-463. http://dx.doi.org/10.1016/S1471-4892 (01) 00080-7.
58. Craig WA. 2001. Does the dose matter? Clin. Infect. Dis. 33(Suppl 3):S233-S237. http://dx.doi.org/10.1086/321854.
59. Andes D. 2001. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr. Opin. Infect. Dis. 14:165-172. http://dx.doi.org/10.1097/00001432-200104000-00010.
60. Ulrich M, Berger J, Moller JG, Doring G. 2005. Moxifloxacin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro. Infection 33(Suppl 2):50-54. http://dx.doi.org/10.1007/ s15010-005-8208-9.
61. Cigana C, Assael BM, Melotti P. 2007. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob. Agents Chemother. 51:975-981. http://dx.doi.org/10.1128/AAC.01142- 06.
62. Bond M, Fabunmi RP, Baker AH, Newby AC. 1998. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 435:29-34. http://dx.doi.org/10.1016/S0014-5793 (98) 01034-5.
63. Barchowsky A, Frleta D, Vincenti MP. 2000. Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergenceof IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine 12:1469-1479. http://dx.doi.org/10.1006/ cyto.2000.0743.
64. Ribeiro CM, Hurd H, Wu Y, Martino ME, Jones L, Brighton B, Boucher RC, O'Neal WK. 2009. Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in welldifferentiated human airway epithelia. PLoS One 4:e5806. http://dx.doi.org/10.1371/journal.pone.0005806.
65. Friedland JS. 2008. Tackling tissue destruction in tuberculosis. Trans. R. Soc. Trop. Med. Hyg. 102:953-954. http://dx.doi.org/10.1016/j.trstmh.2008.05. 008.
66. Ugarte-Gil CA, Elkington P, Gilman RH, Coronel J, Tezera LB, Bernabe-Ortiz A, Gotuzzo E, Friedland JS, Moore DA. 2013. Induced sputum MMP-1, -3 & -8 concentrations during treatment of tuberculosis. PLoS One 8:e61333. http://dx.doi.org/10.1371/journal.pone.0061333.